Article
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2022
Lu Shun, Wang Qiming, Zhang Guojun, Dong Xiaorong, Yang Cheng-Ta, Song Yong, Chang Gee-Chen, Lu You, Pan Hongming, Chiu Chao-Hua, Wang Zhehai, Feng Jifeng, Zhou Jianying, Xu Xingxiang, Guo Renhua, Chen Jianhua, Yang Haihua, Chen Yuan, Yu Zhuang, Shiah Her-Shyong, Wang Chin-Chou, Yang Nong, Fang Jian, Wang Ping, Wang Kai, Hu Yanping, He Jianxing, Wang Ziping, Shi Jianhua, Chen Shaoshui, Wu Qiong, Sun Changan, Li Chuan, Wei Hongying, Cheng Ying, Su Wu-Chou, Hsia Te-Chun, Cui Jiuwei, Sun Yuping, Ou Sai-Hong Ignatius, Zhu Viola W, Chih-Hsin Yang James
Abstract excerpt
INTRODUCTION: Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) with revealed activity against EGFR-sensitizing mutations and EGFR T790M mutation. METHODS: Patients with locally advanced or metastatic NSCLC who developed an EGFR T790M mutation after progression on first- or second-generation EGFR TKI therapy were enrolled in this registrational phase 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.